{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000104","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.772287+00:00","generated_at":"2026-05-16T23:41:12.036340+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intensity Therapeutics Q3 net loss $2.7M; pauses two trials, extends cash runway to Q1 2027","bullets":["Net loss $2.7M for Q3 2025 vs $3.5M YoY; cash $7.1M at Sept 30, plus $6.1M raised in Q4 2025.","INVINCIBLE-4 study paused; plans protocol amendment in Q1 2026 to revise INT230-6 dosing, restart enrollment Q1 2026.","INVINCIBLE-3 study paused since March 2025 due to funding constraints; 21 patients enrolled, plan to restart with sufficient funding.","IT-01 study published in eBioMedicine: 75% disease control rate, 11.9 mo median OS; 20% abscopal effects in >40% tumor burden group.","Capital raises: $7.5M ATM in Q3, $2.1M ATM in Oct, $4.0M registered direct offering in Oct; cash runway extended to Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000104","json":"https://secwatch.observer/filing/0001567264-25-000104.json","markdown":"https://secwatch.observer/filing/0001567264-25-000104.md","text":"https://secwatch.observer/filing/0001567264-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/0001567264-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/intensity-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:41:12.036340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}